Business Segments · Remaining performance obligations

Pharmaceuticals — Remaining performance obligations

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2026

Last reportedQ1 2026

Rolls up toRemaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

How to read this metric

An increase suggests a growing backlog of contracted business and stronger future revenue visibility, while a decrease may indicate shorter contract durations or a slowdown in new business bookings.

Detailed definition

This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partiall...

Peer comparison

Comparable to backlog or deferred revenue metrics in other pharmaceutical or medical device companies with long-term supply or service contracts.

Metric ID: abt_segment_pharmaceuticals_remaining_performance_obligations

Historical Data

1 periods

	Q1 '26
Value	$258.00M

Similar Metrics at Other Companies

Arista NetworksANET View metric

Cisco Systems, Inc.CSCO View metric

Berkshire HathawayBRK.A View metric

Johnson & JohnsonJNJ View metric

Vertex PharmaceuticalsVRTX View metric

Cisco Systems, Inc.CSCO View metric

Frequently Asked Questions

What is Abbott's pharmaceuticals — remaining performance obligations?: Abbott (ABT) reported pharmaceuticals — remaining performance obligations of $258.00M in Q1 2026.
What does pharmaceuticals — remaining performance obligations mean?: The total value of contracted pharmaceutical sales that have not yet been fulfilled or recognized as revenue.